Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis
PaperCitations, authors & open-access status
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 41 citations, 2020 year and closed oa status.
41
Citations
2020
Year
closed
OA Status